Skip to main content
OpenTrials
Completed

NCT Number: NCT00195039

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Weill Medcial College of Cornell University

New York, 10065, United States

About this study

To determine the clinical activity of 177Lu -J591 for the treatment of patients with metastatic, androgen-independent prostate cancer.

Patients will receive a single dose of J591 (total antibody of 20 mg) consisting of antibody chelated with 177Lu at a dose of 65 or 70 mCi/m2 with a specific activity of 12-15 mCi/mg plus non-radiolabeled antibody.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologic diagnosis of prostate adenocarcinoma.
  • Metastatic prostate cancer progressive on imaging studies and/or rising PSA despite adequate medical or surgical castration therapy.
  • Progressed following discontinuation of anti-androgen therapy, if received.
  • Serum testosterone < 50 ng/ml

Exclusion criteria

  • Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment.
  • Use of PC-SPES within 4 weeks of treatment.
  • Use of red blood cell or platelet transfusions within 4 weeks of treatment.
  • Use of hematopoietic growth factors within 4 weeks of treatment.
  • Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
  • Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton.
  • Prior radiation therapy encompassing >25% of skeleton.
  • Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).
  • Active angina pectoris or NY Heart Association Class III-IV.
  • History of deep vein thrombophlebitis and/or pulmonary embolus within 3 months of study entry.
  • Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
  • Prior monoclonal antibody therapy with the exception of ProstaScint®
  • Prior investigational therapy (medications or devices) within 6 weeks of treatment.
  • Known history of HIV

Treatment and study plan

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)

Drug

Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated ("naked") J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min.

Primary outcomes

  1. Define the PSA Response Rate.

    Time frame: At baseline, Day 1, 29, 43, 57, 85, week 18, week 24 & every 12 weeks

    PSA response rate corresponds to change form baseline in PSA at any of the time points specified.

  2. Define the Measurable Disease Response Rate.

    Time frame: Disease will be assessed at baseline and day 85.

    Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.

    Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study

Secondary outcomes

  1. Define the Duration of Biochemical PSA and/or Measurable Disease Response.

    Time frame: At baseline, and up to death

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, Complete Response (CR) = Disappearance of all target lesions, Partial Response (PR) = A </=30% decrease in the sum of the longest diameter of target lesions, taking as reference the Baseline sum longest diameter, Stable Disease (SD) = Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started, Progressive Disease (PD) = A >/=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, or the appearance of one or more new lesions

  2. Define the Toxicity of 177Lu-J591 Given as Single Dose.

    Time frame: From baseline until end of treatment phase (12 weeks)

    Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

    Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL*.

    Grade 3 Severe or medically significant but not immediately life-threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**.

    Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

  3. Define the Incidence of Human Anti-J591 Antibody (HAHA) Response.

    Time frame: HAHA samples will be drawn at baseline and Day 85.

  4. Number of Participants With Hematological Toxicity Relative to Bone Marrow Involvement (Bone Scan Index).

    Time frame: Bone scan will be performed at baseline and Day 85.

    Bone scan score determined for each patient and related to the degree of hematological toxicity quantified by % decline of nadir platelet count relative to baseline count.

  5. Assess the Survival Rate of Patients Following Treatment.

    Time frame: From baseline through study completion

  6. Number of Participants With Targeting of 177Lu-J591 to Known Tumor Sites.

    Time frame: Scans will be performed between day 6 and 8.

Sponsors and collaborators

Lead sponsor

Weill Medical College of Cornell University

Other

Registry information

Official study title

A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Androgen-Independent Prostate Cancer

Important dates

Study start
2004
Primary completion
2012
Study completion
2013
First posted
Sep 19, 2005
Registry last updated
Oct 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.